Titled “Further findings linking SSRIs during pregnancy and persistent pulmonary hypertension of the newborn: clinical implications.”, this article appearing in the October, 2012 edition of CNS Drugs by M. Galbally et al., identifies persistent pulmonary hypertension of the newborn (PPHN) as a potential consequence of SSRI exposure before birth.

Galbally et al. (2012) writes “Persistent pulmonary hypertension of the newborn (PPHN) is a rare but potentially life-threatening neonatal condition. Several authors have suggested that late pregnancy exposure to selective serotonin reuptake inhibitors (SSRIs) may increase the risk of PPHN. This association has been investigated in seven published studies that have shown mixed findings based on diverse methods. Several methodological limitations may account for the diversity of findings, which include, in some studies, a lack of control for well established risk factors for PPHN. The methodological improvement in the most recent study tentatively suggests that infants prenatally exposed to SSRIs are approximately twice as likely to suffer PPHN. Further research on the biological mechanisms involved is required. Clinicians should consider late pregnancy exposure to SSRIs as one of several possible risks for PPHN, which has implications for both prescribing SSRIs to pregnant women and for neonatal care of SSRI-exposed infants.”

Since the manufacturers of SSRIs like Prozac, Paxil, Zoloft, Celexa, and others have failed time and again to adequately inform women of the risk for birth defects, SSRI birth defect lawsuits are currently being filed by the thousands.

If you or a loved one used SSRIs and gave birth to a child with a birth defect or who faced adverse birth outcomes, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of SSRI birth defect lawyers at the information provided below.  We have the compassion, experience, and resources required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

In 2009, S. Alwan and J.M. Friedman, a research duo from the University of British Columbia in Vancouver, published a study titled “Safety of selective serotonin reuptake inhibitors in pregnancy.” in CNS Drugs that provided important insight into the link between gestational exposure to selective serotonin reuptake inhibitor drugs (such as Prozac, Paxil, and Zoloft) and serious congenital malformations.

Because it’s written in plain English and not-so-scientific terms, I have included the abstract below:

“Selective serotonin reuptake inhibitors (SSRIs) are among the most commonly used medications, with a prescription frequency of 2.3% in pregnant women. Although most babies born to women who take SSRIs during pregnancy are normal, there is accumulating evidence that maternal SSRI treatment during pregnancy may cause adverse reproductive outcomes.

[ ]

Maternal SSRI treatment during the first trimester has been implicated in increased risks of birth defects, specifically cardiac abnormalities, in the infant, whereas third-trimester treatment has been linked to various neonatal complications, including symptoms of neonatal withdrawal and toxicity, prematurity, low birth weight and persistent pulmonary hypertension of the newborn. Although data on neurobehavioural and long-term cognitive problems among children of women who were treated with SSRIs during pregnancy remain limited, the possibility of such functional abnormalities is an additional concern.

[ ]

On the other hand, untreated maternal depression also carries serious risks for both the mother and the baby, and SSRIs are one of the best available treatments. Thus, pregnant women who require treatment for depression and their physicians often face a difficult choice regarding the use of SSRIs.”

While untreated maternal depression does in fact constitute a serious problem, it is of utmost concern that expecting mothers make informed decisions regarding drug use during pregnancy.  And because the manufacturers of many SSRI drugs have failed time and again to adequately inform women of these risks, a number of SSRI birth defect lawsuits have been filed.

If you or a loved one used SSRIs and gave birth to a child with a congenital malformation or who had perinatal complications, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of SSRI birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

Published in May, 2009 in Pharmacopsychiatry by a team of Australian researchers led by J. Rampono, an article titled “Placental transfer of SSRI and SNRI antidepressants and effects on the neonate.” provides further evidence that drugs such as Celexa, Lexapro, Prozac, Paxil, Zoloft, Effexor and others may cross the placenta and affect a developing fetus.

The team writes “We investigated placental transfer and neurobehavioural effects in neonates exposed to citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline (SSRI’s), or to venlafaxine (an SNRI)” and states that “Women receiving antidepressants during pregnancy and their neonates were studied. Cord and maternal drug concentrations were measured at birth and in the neonates plasma on day 3. Neonates were also assessed using a range of neurobehavioral tests and compared to controls.”

Results showed that “Neonatal abstinence scores were significantly higher (p<0.05) in exposed infants than controls on day 1. Brazelton scores for habituation, social-interactive, motor and autonomic clusters, and serotonin scores were significantly greater (p<0.05) in exposed infants.”  Accordingly, Rampono et al. (2009) concluded that “Transfer of SSRIs and SNRIs across the placenta was substantial.”

Because so many expecting mothers have used these drugs unaware of the risk for perinatal complications, adverse birth outcomes, or congenital malformations, a number of SSRI birth defect lawsuits have been filed.

If you or a loved one used SSRIs and gave birth to a child with a congenital malformation or who had perinatal complications, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of SSRI birth defect lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

Over the past several decades, a number of studies have linked Celexa exposure and birth defects.  This morning, I found several more, some of which are summarized below.  For more articles demonstrating the connection between birth defects and Celexa, follow the preceding link.

In a 2013 edition of Fetal and Pediatric Pathology, an article by G. Eleftheriou et al., titled “Neonatal toxicity following maternal citalopram treatment.”, important insight is given into the link between adverse birth outcomes and neonatal exposure to selective serotonin reuptake inhibitor drugs.  In this case, the focus was on Celexa.  The team writes: “Late gestational exposure to citalopram, may be associated with a neonatal toxicity syndrome with immediate onset at birth or soon after birth and sometimes may be mistaken for neonatal withdrawal syndrome.”

Studying a single case of prenatal Celexa (citalopram) exposure, the team found that “Fifteen minutes after birth, the baby became hypertonic”, and concludes that “Neonatal serotonin toxicity due to citalopram seems the most likely mechanism”.

A study titled “Platelet serotonin in newborns and infants: ontogeny, heritability, and effect of in utero exposure to selective serotonin reuptake inhibitors.” by G.M. Anderson and a team of researchers from Yale University School of Medicine published in a 2004 edition of  Pediatric Research studied the physiological effects of prenatal SSRI exposure, focusing on Prozac, Zoloft, and Celexa.

In this study, “The effects of in utero exposure to selective serotonin reuptake inhibitors (SSRI, including fluoxetine, sertraline, and citalopram) were examined by comparing cord blood 5-HT levels in exposed and unexposed newborns.”  Results demonstrated that “although platelet 5-HT is low at birth, values quickly increase and stabilize at near-adult levels by 1 mo of age. Gestational exposure to SSRI appears to substantially reduce platelet 5-HT uptake in the fetus, strongly suggesting that such exposure has important physiologic effects.” (emphasis added)

Published in the August, 2002 edition of Clinical Pharmacology and Therapeutics, an article by a Finnish team of researchers led by T. Heikkinen, titled “Citalopram in pregnancy and lactation.” makes brief but important mention of the danger of prenatal exposure to Celexa and other SSRI drugs.  Studying only 11 mothers who used Celexa while pregnant and comparing them to 10 control mother-child sets, the results of this study are inherently weak.  Nonetheless, the team acknowledges that “maternal therapeutic drug monitoring of citalopram should be recommended to minimize fetal exposure”.

Because many women have used SSRI drugs unaware of the risk for adverse birth outcomes, a number of Celexa® birth defects lawsuits and SSRI birth defect lawsuits have been filed.

If you or a loved one used Celexa or another SSRI during pregnancy and gave birth to a child with a congenital malformation or who had perinatal complications, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Celexa® birth defects lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

In a 2006 edition of Neuropsychopharmacology, an article by D. Maciag et al. titled “Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry.” provides important insight into the risks of neonatal exposure to selective serotonin reuptake inhibitor drugs before birth.

The team writes “A significant fraction of infants born to mothers taking selective serotonin reuptake inhibitors (SSRIs) during late pregnancy display clear signs of antidepressant withdrawal indicating that these drugs can penetrate fetal brain in utero at biologically significant levels” and cites that “Previous studies in rodents have demonstrated that early exposure to some antidepressants can result in persistent abnormalities in adult behavior and indices of monoaminergic activity.”

Studying rats exposed to Celexa (citalopram) before birth, the team found that “neonatal exposure to citalopram produces selective changes in behavior in adult rats including increased locomotor activity and decreased sexual behavior similar to that previously reported for antidepressants that are nonselective monoamine transport inhibitors. These data indicate that the previously reported neurobehavioral effects of antidepressants are a consequence of their effects on the serotonin transporter. Moreover, these data argue that exposure to SSRIs at an early age can disrupt the normal maturation of the serotonin system and alter serotonin-dependent neuronal processes.”

Because of discrepancies between data like this and SSRI warning labels, a number of SSRI birth defect lawsuits have been filed.   If you or a loved one used Celexa or another SSRI during pregnancy and gave birth to a child with a congenital malformation or who had perinatal complications, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Celexa® birth defects lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

In 2011, a team of medical researchers from Australia led by L. Colvin, published a study titled “Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy.” in Birth Defects Research, providing further evidence of a link between prenatal exposure to SSRI drugs and birth defects.  For clarity, “SSRIs” stands for selective serotonin reuptake inhibitors (SSRIs) and is a class of psychotropic medications aimed at raising levels of synaptic serotonin, a neurotransmitter key in the regulation of mood, sleep, and appetite, and that plays an important role in fetal development, particularly cardiovascular development.  Some common SSRI drugs are Prozac, Paxil, Celexa, Effexor, and Zoloft.

The authors state “Using data linkage of population-based health datasets from Western Australia and a national pharmaceutical claims dataset, our study included 123,405 pregnancies from 2002 to 2005. There were 3764 children born to 3703 women who were dispensed an SSRI during their pregnancy.”

Results showed that women who used SSRI drugs during pregnancy were 40% more likely to give birth prematurely, and 20% more likely to bear children with low birth weight.  Further, “There was an increased risk of major cardiovascular defects (OR, 1.6; 95% CI, 1.1-2.3). The children of women dispensed citalopram during the first trimester had an increased risk of vesicoureteric reflux (OR, 3.1; 95% CI, 1.3-7.6).”

That means that heart defects were 60% more common amongst babies born to mothers who used SSRIs during pregnancy, and that babies whose mothers used Celexa (citalopram) during the first three months of pregnancy were more than three times as likely to be born with vesicoureteric reflux.

Because many women have used Celexa or other SSRI drugs during pregnancy unaware of these risks, a number of Celexa® birth defects lawsuits have been filed.

If you or a loved one used Celexa and gave birth to a child with a congenital malformation or who had perinatal complications, you may be entitled to significant financial compensation.  For a free, no-obligation case consultation, contact our team of Celexa® birth defects lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you deserve.  Call today and see how we can help.

(855) 452 – 5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

Studies have shown that women suffering from depression during pregnancy can put the child at risk of developing malformations.  As such, selective serotonin reuptake inhibitors (SSRIs) are most commonly prescribed to the mother to avoid such complications.  Unfortunately, using these drugs during pregnancy may also put the child at risk of malformations.  To date, the research is still inconsistent in illustrating a causal link between pregnant women using SSRI’s and malformations of the child, but the association is clear.

One study analyzing the data on the effects of SSRI usage during pregnancy is titled “Increasing the risk of spontaneous abortion and major malformations in newborns following use of serotonin reuptake inhibitors during pregnancy: A systematic review and updated meta-analysis.”  The study was conducted by Nikfar et al. within the Department of Toxicology and Pharmacology Research Center of the Tehran University of Medical Sciences.  The authors’ stated goal of the study was to update their previous meta-analysis about the outcomes of pregnancies following usage of SSRIs.

Databases were searched from 1990 to 2012, in order to collect studies to include in this meta-analysis.  The studies investigated the outcomes of pregnancies following exposure to any “therapeutic dosage” of any SSRI including fluoxetine, paroxetine, citalopram, escitalopram, sertraline, and fluvoxamine.  The outcomes considered were spontaneous abortion, major malformations, cardiovascular malformations, and minor malformations.  The results of the meta-analysis revealed odds ratio values of 1.87 (95% CI: 1.5 to 2.33, P< 0.0001) for spontaneous abortion, 1.272 (95% CI: 1.098 to 1.474, P = 0.0014) for major malformations, 1.192 (95% CI: 0.39 to 3.644, P= 0.7578) for cardiovascular malformations, and 1.36 (95% CI: 0.61 to 3.04, P= 0.4498) for minor malformations.  After considering the data, the authors stated “The results demonstrated that SSRIs increase the risk of spontaneous abortion and major malformations during pregnancy while they don’t increase the risk of cardiovascular malformations and minor malformations. Our previous meta-analysis only showed an increase in the risk of spontaneous abortion following the use of SSRIs during pregnancy.”  The authors go on to explain that the differing conclusions of the meta-analyses may be due to an increase in the number of studies included and/or the addition of two new SSRIs (citalopram and escitalopram).

Due to the fact that many women have used SSRI during pregnancy unaware of the risks associated with their use, a number of SSRI birth defect lawsuits have been filed.  If you or a loved one used SSRIs during pregnancy and your child was born with a congenital malformation, please do not hesitate to contact our team of SSRI birth defects lawyers at the information provided below.  We have the skills, resources, and experience required to win the justice you deserve.

(855) 452 – 5529

justinian@dangerousdrugs.us

Call today and see how we can help!

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

The objective of a study titled “Neonatal Abstinence Syndrome After in Utero Exposure to Selective Serotonin Reuptake inhibitors in Term Infants”, written by researchers from the Neonatal Intensive Care Unit at Schneider Children’s Medical Center of Israel, led by R. Levinson-Castiel was to determine the prevalence and clinical characteristics of neonatal abstinence syndrome in neonates both exposed and not exposed to selective serotonin reuptake inhibitors in utero.  The study was a cohort study taken place in tertiary care centers.  In all, there were 120 term infants used in this study.  Sixty of these infants had prolonged utero exposure to paroxetine hydrochloride (Paxil), fluoxetine (Prozac), citalopram hydrobromide (Celexa), sertraline hydrochloride (Zoloft), and venlafaxine hydrochloride (Effexor).

Levinson-Castiel writes “Neonatal abstinence syndrome was assessed with the Finnegan score as follows: score of 8 or above, severe; score of 4 to 7, mild; and score of 0 to 3, normal. All infants were followed up with a standardized protocol that included repeated Finnegan score assessments and cardiorespiratory monitoring until normalization of the Finnegan score.”

Shockingly, it was found that eight of ten neonates exposed to SSRIs showed some symptoms of a neonatal abstinence syndrome, and that 100 percent of all nonexposed neonates had a normal Finnegan score.  Levinson-Castiel further states “In neonates who developed severe symptoms, the maximum mean daily Finnegan scores were recorded within 2 days after birth, although maximum individual scores were recorded as long as 4 days after birth.”  Though long term effects of SSRI exposure are yet to be determined, neonatal abstinence syndrome was recorded in 30 percent of the neonates exposed to SSRIs.

If you or a loved one used an SSRI during pregnancy and your child was born with a congenital malformation, your family may be entitled to significant financial compensation from the manufacturer of the drug used for the undue injury caused to those close to you.  For a free, no-obligation case consultation, contact our team of Paxil® birth defects lawyers, Prozac® birth defects lawyers, Celexa® birth defects lawyers, Zoloft® birth defects lawyers, and Effexor® birth defects lawyers at the information provided below.  We have the experience, resources, and skills required to win the justice you and your loved ones deserve.

(855) 452 – 5529

justinian@dangerousdrugs.us

Call today and see how we can help!

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

A study conducted by the Department of Psychological Medicine, King Edward Memorial Hospital for Women, Subiaco, Australia, titled “Placental Transfer of SSRI and SNRI Antidepressants and Effects On The Neonate”, investigated placental transfer and neurobehavioural effects in neonates exposed to venlafaxine (Effexor), sertraline (Zoloft), paroxetine (Paxil), fluvoxamine, fluoxetine (Prozac), escitalopram, and citalopram (Celexa).  The neonates of women receiving antidepressants during pregnancy were studied and cord and maternal drug concentrations were measured at birth.  Neurobehavioral tests were used to assess neonates and compared to controls.

Rampono states “Median cord/maternal distribution ratio was 0.7-0.86 (range) for SSRIs, 0.72 for the SNRI venlafaxine and 1.08 for the O-desmethyl metabolite.”  It was shown that exposed infants had abstinence scores significantly higher neonatal abstinence scores than controls on day 1.  Exposed infants also showed significantly greater brazelton scores for habituation, social interactive, motor and autonomic clusters, and serotonin.

This study found that transfer of SSRIs and SNRIs across the placenta were substantial.  Author Rampono J. further states that “Neonates developed mild behavioral symptoms in the early perinatal period but these were self-limiting and similar for both SSRIs and the SNRI venlafaxine.”

If you or a loved one used SSRI during pregnancy and your child was born with a birth defect, your family may be entitled to significant financial compensation from the manufacturer of the drug used for the undue injury, pain, and suffering incurred through no fault of your own.  At your convenience, contact our team of Effexor® birth defects lawyers, Zoloft® birth defects lawyers, Paxil® birth defects lawyers, Prozac® birth defects lawyers, Celexa® birth defects lawyers, and SSRI birth defect lawyers to receive a free, no-obligation case consultation.

(855) 452 – 5529

justinian@dangerousdrugs.us

Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.

A team of medical researchers led by F. Rodriguez-Porcel (2011), from the Department of Psychiatry & Human Behavior at The University of Mississippi Medical Center in Jackson, conducted a study titled “Neonatal Exposure of Rats to Antidepressants Affects Behavioral Reactions to Novelty and Social Interactions in a Manner Analogous to Autistic Spectrum Disroders”, where it is demonstrated that neonatal exposure to selective serotonin reuptake inhibitors may have continuous effects on Long Evans rats.  Rodriguez-Porcel F states “Hyperserotoninemia and altered sensory processing are reported in autistic spectrum disorders (ASD). We hypothesized that early life exposure to SSRIs alters sensory processing, disrupts responses to novelty, and impairs social interactions in a manner similar to that observed in ASD.” (emphasis added)

Hyperserotoninemia is a very dangerous and life threatening reaction to a drug due to an overdose of a particular drug, or the recreational use of some drugs.  Hyperserotoninemia can be predicted due to excess serotonergic activity of the central nervous system.  Female and male Long Evans rats were given citalopram, buproprion, or fluoxetine from postnatal day.  These rats were tested for a novel tone before weaning, then they were tested for a response to a novel object and to a novel conspecific.

Rodriguez-Porcel F. goes on to state “In addition, rats were assessed for juvenile play behaviors (P32-P34) and later, we assessed sexual response to an estrus female in male rats (P153-184). Antidepressant exposure increased freezing after tone, diminished novel object exploration, and reduced conspecific interaction up to 3× compared to saline exposed rats.”  It was found that juvenile play greater reduced in antidepressant exposed males, and that exposure to the SSRIs disrupted male sexual behaviors and specific male responses to female proceptive behaviors were diminished.  The study concluded that neonatal exposure to antidepressants in rats lead to sensory and social abnormalities.

This study may be used as evidence in a Celexa birth defects lawsuit, a Wellbutrin birth defects lawsuit, or a Prozac lawsuit to help demonstrate to a court that the manufacturers of these drugs knew, or should have know, the risks associated with their products.  Due to the fact that many women have used SSRIs during pregnancy, uninformed about the risk for birth defects associated with these drugs, SSRI birth defects lawsuits are currently being filed all over the world.

If you or a loved one used SSRIs during pregnancy and your child was born with autism, contact our team of Celexa® lawyers, Prozac® lawyers, Wellbutrin® lawyers, and SSRI autism lawyers at the information provided below.  We have the resources, skills, and experience required to win the justice you deserve, even from the largest of pharmaceutical manufacturers.

(855) 452 – 5529

justinian@dangerousdrugs.us

Call today and see how we can help! Our SSRI Birth Defects Lawsuit Information page is a great place to start if you have any questions about SSRIs and Birth Defects.